404
+1-313-307-4176
Long Acting Injectable Anti Psychotic Market Report
Long-Acting Injectable Anti-Psychotic Market Size, Share, Trends, Forecast & Competitive Analysis: 2022-2026
Long-Acting Injectable Anti-Psychotic Market report is segmented By Product (Sustenna/ Trinza, Risperdal Consta, Abilify Maintena, Zyprexa, Aristada and Other), Application (Schizophrenia, Other), and Region - COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Long Acting Injectable Anti-Psychotic market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The Long-Acting Injectable Anti-Psychotic Market is expected to grow at a healthy CAGR during the forecast period.
Figure: Long-Acting Injectable Anti-Psychotic Market Size, 2020-2026 (USD Million)
Wish to know more about the market assumptions? Click here to get a free sample.
Anti-psychotic is a type of medication primarily used to manage psychosis which includes hallucinations, delusion, and paranoia in various psychotic disorders. Long-acting injectable (LAI) antipsychotic is primarily used to treat patients having schizophrenia disorder. It can be taken every two to four weeks or every three months instead of consuming pills on a daily basis.
Key players operating in the global Long-Acting Injectable Anti-Psychotic Market are-
Rising demand for advanced healthcare solutions coupled with increasing health awareness is likely to add to the market growth substantially.
The growth of the global long-acting injectable anti-psychotic market is primarily driven by an increasing number of people suffering from schizophrenia. It is diagnosed more frequently in males as compared to females.
Growing preference for long-acting injectable anti-psychotics over oral medications for people suffering from mental disorders is likely to propel the market growth at a significant rate during the review period.
However, the side effects of taking long-acting injectable anti-psychotics are likely to affect the market growth negatively.
The COVID-19 outbreak did not affect the growth of the long-acting injectable anti-psychotic market. The national healthcare organizations in many European countries and the US allowed the ongoing usage of long-term injectable anti-psychotics for patients suffering from mental disorders and having high-risk chronic illnesses. The majority of mental healthcare facilities allowed the continuation of visits as it is an essential clinical procedure.
Based on application, the market has been segmented into schizophrenia and others. The schizophrenia segment accounted for the largest market share in 2020 and is projected to grow at the fastest CAGR during the review period. The segment growth can be attributed to the rising incidence of people suffering from schizophrenia. Schizophrenia is a serious mental disorder in which people abnormally infer reality.
Geographically, the market in North America accounted for the largest market share in 2020. The regional market growth can be attributed to the increasing number of people suffering from mental disorders coupled with the expanding geriatric population and the presence of established healthcare infrastructure. The market in Asia-Pacific is expected to register the fastest growth during the review period on account of rising consumer awareness and increasing spending on healthcare.
Want to know the full scope of the report? Register Here
The following is a list of the customers that the Global Long-Acting Injectable Anti-Psychotic market aims to convert the most:
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
Johnson & Johnson (The U.S), Eli Lily and Company (The U.S), Alkeremes Public Limited Company (Ireland), H. Lundbeck A/S (Denmark), Pfizer Inc. (The U.S), GlaxoSmithKline plc (UK), Lupin Limited (India), MedinCell S.A. (France), Zogenix (The U.S) and Durect Corporation (The U.S) are among the key players in the long acting injectable anti-psychotic market.
North America accounted for the largest share in the long acting injectable anti-psychotic market in 2020.
Asia-pacific is expected to register the fastest growth in the long acting injectable anti-psychotic market in the coming years.
The schizophrenia segment is expected to grow at the fastest CAGR in the long acting injectable anti-psychotic market in the years to come.
Rising demand for advanced healthcare solutions coupled with increasing health awareness, increasing number of people suffering from schizophrenia are the factors driving the growth of long acting injectable anti-psychotic market.
Long-acting injectable anti-psychotic manufacturers, Long-acting injectable anti-psychotic suppliers, Long-acting injectable anti-psychotic distributors, Organizations, Government bodies are the target audience in the long acting injectable anti-psychotic market.
WE ACCEPT
